Stocks Health care CGEN
NASDAQ · Health careCompugen Ltd (CGEN)
Compugen Ltd reported revenue of $72.8M in fiscal 2025, up 161.1% from a year earlier. Net income was $35.3M, a net margin of 48.6%. Operating cash flow minus capital spending left $31.3M of free cash flow in fiscal 2025. At December 31, 2025 it held $90.6M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 2, 2026.
Key facts about Compugen Ltd
- Net worth
- Compugen Ltd has a market value (market cap) of $196.3M at the latest share price, and shareholders' equity of $102.7M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $72.8M (+161.1% year on year), with net income of $35.3M.
- Cash flow
- In fiscal 2025 operations brought in $31.6M of cash; after $306K of capital spending, free cash flow was $31.3M.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on March 2, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Compugen Ltd does
Compugen Ltd is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CGEN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $72.8M | $35.3M | $0.38 | $31.3M |
| 2024 | $27.9M | -$14.2M | -$0.16 | $49.5M |
| 2023 | $33.5M | -$18.8M | -$0.21 | -$36.1M |
| 2022 | $7.5M | -$33.7M | -$0.39 | -$34.6M |
| 2021 | $6M | -$34.2M | -$0.41 | -$23M |
| 2020 | $2M | -$29.7M | -$0.37 | -$28.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CGEN ranks in Health care
Latest SEC filings
What Compugen Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- September 10, 2026
- August 3, 2026
- August 3, 2026
- May 18, 2026Form F-3 filing F-3
- May 18, 2026
- March 2, 2026Annual report (foreign issuer) 20-F · period to December 31, 2025Revenue rose 161% to $72.8M versus the prior year; diluted EPS $0.38 versus -$0.16.
- March 2, 2026
- February 12, 2026
- December 17, 2025
Insider trades
What the people running Compugen Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 29, 2026 | Mahler MichelleChief Medical Officer | Received as pay | 13,500 | - |
| July 29, 2026 | Zweifach Sanford SDirector | Received as pay | 7,500 | - |
| July 29, 2026 | Halevy GileadDirector | Received as pay | 7,500 | - |
| July 29, 2026 | Hukkelhoven MathiasDirector | Received as pay | 7,500 | - |
| July 29, 2026 | Livnat Savitzky KinneretDirector | Received as pay | 7,500 | - |
| July 29, 2026 | Kredo Russo SharonSVP, Research & Discovery | Received as pay | 18,000 | - |
| July 29, 2026 | Perry EranDirector | Received as pay | 7,500 | - |
| July 29, 2026 | Silberman DavidChief Financial Officer | Received as pay | 19,500 | - |
Who owns CGEN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
10 insiders reported holding 282,812 shares in total, about $586.8K at the last price.
| Holder | Shares |
|---|---|
| Silberman DavidChief Financial Officer | 55,000 |
| Levine ZuritSVP, Business Development | 47,375 |
| Kredo Russo SharonSVP, Research & Discovery | 37,500 |
| Mahler MichelleChief Medical Officer | 36,625 |
| Livnat Savitzky KinneretDirector | 20,850 |
| Zweifach Sanford SDirector | 20,180 |
| Halevy GileadDirector | 18,907 |
| Perry EranDirector | 17,500 |
| Hukkelhoven MathiasDirector | 17,500 |
| Ophir EranPresident and CEO, Director | 11,375 |
Questions about CGEN
What does Compugen Ltd do?
Compugen Ltd is a company in the Health care sector, listed on NASDAQ as CGEN. Its shares trade on NASDAQ under the ticker CGEN.
What is Compugen Ltd's net worth?
Compugen Ltd has a market value (market cap) of $196.3M at the latest share price, and shareholders' equity of $102.7M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Compugen Ltd profitable?
Yes. In fiscal 2025 it reported net income of $35.3M on revenue of $72.8M, a net margin of 48.6%.
How much revenue does Compugen Ltd make?
In fiscal 2025 Compugen Ltd reported revenue of $72.8M. That is 161.1% more than a year earlier.
When did Compugen Ltd last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 2, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from November 9, 2026.
Similar companies
Compare CGEN with
Follow CGEN
Get an email when Compugen Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Compugen Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.